BioCentury
ARTICLE | Clinical News

Jadenu deferasirox regulatory update

April 13, 2015 7:00 AM UTC

FDA approved Jadenu deferasirox from Novartis to treat chronic iron overload in patients ages >=10 with non-transfusion-dependent thalassemia (NTDT) syndromes and due to blood transfusions in patients...